Search Within

Lisa Bodei

Formats
  1. Meeting Abstract (69)
  2. Journal Article (62)
  3. Review (34)
  4. Book Section (18)
  5. Editorial (12)
  6. Guidelines (9)
  7. Conference Paper (2)
  8. Miscellaneous (2)
  9. Book Whole (1)
  10. Correspondence (1)
Groups
  1. Molecular Imaging and Therapy Service (210)
  2. Radiology, Department of (210)
  3. Sloan Kettering Institute Postdocs (210)
  4. Center for Pancreatic Cancer Research (35)
  5. Department of Medicine (33)
  6. Solid Tumor Oncology Division (31)

More Groups

People
  1. Heiko Schoder (20)
  2. Jason Lewis (18)
  3. Diane Reidy (17)
  4. Joseph O'Donoghue (13)
  5. Simone Krebs (11)
  6. Michael Morris (10)

More People

Years
  1. 2025 (7)
  2. 2024 (15)
  3. 2023 (26)
  4. 2022 (16)
  5. 2021 (27)
  6. 2020 (31)

More Years

Publications
  1. Journal of Nuclear Medicine (36)
  2. Neuroendocrinology (32)
  3. European Journal of Nuclear Medicine and Molecular Imaging (26)
  4. Pancreas (16)
  5. Journal of Clinical Oncology (15)
  6. Radiopharmaceutical Therapy (9)

More Publications

Publishers
  1. Springer (48)
  2. Society of Nuclear Medicine (36)
  3. S. Karger AG (32)
  4. Lippincott Williams & Wilkins (22)
  5. American Society of Clinical Oncology (15)
  6. Elsevier Inc. (11)

More Publishers

Results (210)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Caveat emptor: Let our acclaim of the apotheosis of PRRT not blind us to the error of Prometheus
    Editorial

    Bodei, L.; Herrmann, K.; Baum, R. P.; Kidd, M.; Malczewska, A.; Modlin, I. M.
    Journal of Nuclear Medicine (2019)

    Fulltext@MSK | Save
  • Enchondroma of tibia as potential false-positive finding on (68)Ga-DOTATOC PET/CT scan
    Journal Article

    Mahajan, S.; Bodei, L.; Huicochea Castellanos, S.; Grewal, R. K.
    Clinical Nuclear Medicine (2019)

    Fulltext@MSK | Save
  • Lanreotide depot/autogel before, during, and after peptide receptor radionuclide therapy (PRRT) in advanced neuroendocrine tumors (NETs): Data from the PRELUDE study
    Meeting Abstract

    Prasad, V.; Srirajaskanthan, R.; Toumpanakis, C.; Grana, C. M.; Baldari, S.; Shah, T.; Lamarca, A.; Courbon, F.; Scheidhauer, K.; Baudin, E.; more...
    Journal of Clinical Oncology (2018)

    Fulltext@MSK | Save
  • Peptide receptor radionuclide therapy (PRRT) transcriptomic signature in blood for prediction of (177)Lu-octreotate efficacy
    Meeting Abstract

    Bodei, L.; Kidd, M. S.; Singh, A.; van der Zwan, W. A.; Severi, S.; Drozdov, I.; Cwikla, J. B.; Baum, R. P.; Kwekkeboom, D. J.; Paganelli, G.; more...
    Journal of Clinical Oncology (2018)

    Fulltext@MSK | Save
  • Neuroendocrine gene transcripts: The role of molecular biomarkers in diagnosis and management
    Book Section

    Bodei, L.; Kidd, M.; Chung, K. M.; Modlin, I.
    In Giovanella, L. (Eds.) Atlas of Thyroid and Neuroendocrine Tumor Markers (2018)

    Fulltext@MSK | Save
  • The molecular biology of NET: Current status and evaluation of biomarkers for prediction and prognosis
    Book Section

    Kidd, M.; Ferone, D.; Albertelli, M.; Nazzari, E.; Bodei, L.; Modlin, I. M.
    In Colao, A.; Faggiano, A.; de Herder, W. (Eds.) Neurodendocrine Tumors in Real Life: From Practice to Knowledge (2018)

    Fulltext@MSK | Save
  • Tumour growth rate (TGR) when using lanreotide Autogel® (LAN) before, during and after peptide receptor radionuclide therapy (PRRT) in advanced neuroendocrine tumours (NETs)
    Meeting Abstract

    Prasad, V.; Srirajaskanthan, R.; Grana, C. M.; Baldari, S.; Shah, T.; Lamarca, A.; Courbon, F.; Scheidhauer, K.; Baudin, E.; Truong-Thanh, X. M.; more...
    Annals of Oncology (2018)

    Fulltext@MSK | Save
  • The value of somatostatin receptor scintigraphy (SRS) in patients with NETG1/G2 neuroendocrine neoplasms of the small intestine (SI-NENs)
    Meeting Abstract

    Konsek, S. J.; Kolasinska-Cwikla, A. D.; Lewczuk, A.; Kidd, M.; Buscombe, J. R.; Bodei, L.; Cichocki, A.; Roszkowska-Purska, K.; Cwikla, J. B.; Modlin, I. M.
    European Journal of Nuclear Medicine and Molecular Imaging (2018)

    Fulltext@MSK | Save
  • Dosimetry of LUTATHERA in patients with advanced midgut neuroendocrine tumors: Results of the phase III NETTER-1 sub-study
    Meeting Abstract

    Bodei, L.; Cremonesi, M.; Ferrari, M.; Krenning, E.; Sierra, M. L.; Erion, J. L.; Santoro, P.; Chicco, D.; Mariani, M. F.
    European Journal of Nuclear Medicine and Molecular Imaging (2018)

    Fulltext@MSK | Save
  • Combined 177Lu-DOTATATE and metronomic capecitabine in gastro-entero-pancreatic neuroendocrine tumors with high glucose metabolism: Preliminary data of a phase II prospective trial
    Meeting Abstract

    Paganelli, G.; Nicolini, S.; Grana, C. M.; Bodei, L.; Di Mauro, F.; Tardelli, E.; Monti, M.; Ferroni, F.; Caroli, P.; Ibrahim, T.; more...
    European Journal of Nuclear Medicine and Molecular Imaging (2018)

    Fulltext@MSK | Save